17 May 2023
The Medicines Patent Pool (MPP) is pleased to announce its official affiliation with the United Nations Principles for Responsible Investment (UNPRI) as a network supporter. This partnership reinforces MPP’s commitment to sustainable and responsible investment practices, aligning with its mission to address global health challenges and promote equitable access to life-saving treatments.
As a network supporter of UNPRI, MPP joins a diverse community of investors, asset managers, and service providers committed to incorporating environmental, social, and governance (ESG) factors into their investment decisions, in line with the six principles of responsible investment:
This collaboration underlines MPP’s dedication to health equity, transparency, and promoting long-term sustainable access solutions for the pharmaceutical industry.
By endorsing the UNPRI framework, MPP will engage with signatory investors to align on strategies to enable access to essential medicines in low- and middle-income countries (LMICs). This partnership will enable MPP to contribute further to the UN’s Sustainable Development Goals (SDGs) and amplify efforts to increase access to affordable, high quality medicines for those in need in LMICs.
By joining forces with UNPRI, we aim to leverage our expertise and influence to drive positive change in the pharmaceutical industry and advance global health equity.
MPP has a proven track record of collaboration with governments, industry partners, civil society organisations, and other stakeholders to facilitate the licensing of essential medicines, including antiretrovirals for HIV treatment and other priority health products. With this new partnership, MPP will strengthen its advocacy for responsible investment practices, encouraging stakeholders to prioritise affordable access to medicines, technological innovation, and social sustainability.
For more information about the Medicines Patent Pool and its commitment to responsible investment, click here.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.